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Pediatric Bacterial Meningitis Surveillance in Niger: 
Increased Importance of Neisseria meningitidis Serogroup 
C, and a Decrease in Streptococcus pneumoniae Following 
13-Valent Pneumococcal Conjugate Vaccine Introduction
Mamadou Kourna Hama,1,a Dam Khan,2,a Boubou Laouali,1 Catherine Okoi,2 Abdoulaye Yam,3 Moussa Haladou,3 Archibald Worwui,2  
Peter Sylvanus Ndow,2 Ricardo Nse Obama,3, Jason M. Mwenda,4 Joseph Biey,4 Bernard Ntsama,5 Brenda A. Kwambana-Adams,2 and Martin Antonio2,6; 
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1Laboratoire Hopital National de Niamey, Niger; 2World Health Organization (WHO) Collaborating Centre for New Vaccines Surveillance, Medical Research Council Unit The Gambia at the London 
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Background. Meningitis is endemic in Niger. Haemophilus influenzae type b (Hib) vaccine and the 13-valent pneumococcal 
conjugate vaccine (PCV13) were introduced in 2008 and 2014, respectively. Vaccination campaign against Neisseria meningitidis 
serogroup A was carried out in 2010–2011. We evaluated changes in pathogen distribution using data from hospital-based surveil-
lance in Niger from 2010 through 2016.
Methods. Cerebrospinal fluid (CSF) specimens from children <5  years old with suspected meningitis were tested to detect 
vaccine-preventable bacterial pathogens. Confirmatory identification and serotyping/grouping of Streptococcus pneumoniae, 
N. meningitidis, and H. influenzae were done. Antimicrobial susceptibility testing and whole genome sequencing were performed on 
S. pneumoniae isolates.
Results. The surveillance included 2580 patients with suspected meningitis, of whom 80.8% (2085/2580) had CSF collected. 
Bacterial meningitis was confirmed in 273 patients: 48% (131/273) was N.  meningitidis, 45% (123/273) S.  pneumoniae, and 7% 
(19/273) H. influenzae. Streptococcus pneumoniae meningitis decreased from 34 in 2014, to 16 in 2016. PCV13 serotypes made up 
88% (7/8) of S. pneumoniae meningitis prevaccination and 20% (5/20) postvaccination. Neisseria meningitidis serogroup C (NmC) 
was responsible for 59% (10/17) of serogrouped N. meningitidis meningitis. Hib caused 67% (2/3) of the H. influenzae meningitis 
isolates serotyped. Penicillin resistance was found in 16% (4/25) of S. pneumoniae isolates. Sequence type 217 was the most common 
lineage among S. pneumoniae isolates.
Conclusions. Neisseria meningitidis and S. pneumoniae remain important causes of meningitis in children in Niger. The decline 
in the numbers of S. pneumoniae meningitis post-PCV13 is encouraging and should continue to be monitored. NmC is the predom-
inant serogroup causing N. meningitidis meningitis.
Keywords. meningitis; Niger; cerebrospinal fluid; N. meningitidis; S. pneumoniae.
Niger is one of the 26 countries situated within the African “men-
ingitis belt,” which spans from Senegal in the west to Ethiopia in 
the east. Bacterial meningitis is endemic in Niger and the burden 
of disease is worsened by the periodic occurrence of epidemics 
in the region, mainly caused by Neisseria meningitidis. In 2015, 
a meningitis outbreak attributed to N. meningitidis serogroup C 
(NmC) occurred, affecting nearly 10 000 people [1–3]. In 2009 
and 2006, meningitis outbreaks caused by N. meningitidis sero-
groups A (NmA) and X (NmX), respectively, were reported [4, 
5]. Haemophilus influenzae and Streptococcus pneumoniae are 2 
other important pathogens that contribute significantly to the 
bacterial meningitis burden within Niger [6].
The World Health Organization (WHO) has prioritized the 
implementation of vaccines that can prevent bacterial meningitis 
globally, especially those targeting young children. With huge fi-
nancial support from Gavi, the Vaccine Alliance, the H. influenzae 
type b (Hib) conjugate vaccine and 13-valent pneumococcal con-
jugate vaccine (PCV13) were introduced into the Niger Expanded 
Programme on Immunization (EPI) in 2008 and 2014, respec-
tively. Mass vaccination with MenAfriVac, which protects against 
NmA, was conducted between September 2010 and December 
2011 [7]; plans to introduce MenAfriVac into the Niger routine 
EPI are under way. The coverage for 3 doses of PCV13 in Niger has 
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progressively increased from 13% in 2014 to 76% in 2016 according 
to WHO/United Nations Children’s Fund estimates, and coverage 
for the 3 doses of Hib vaccine was estimated to increase from 71% 
to 80% from 2010 to 2016 [8]. Coverage of the MenAfriVac conju-
gate vaccine during the vaccination campaign was 76% [7].
Pediatric bacterial meningitis (PBM) surveillance is neces-
sary to monitor the burden and microbiologic etiology of men-
ingitis, particularly within the context of vaccine introduction. 
The WHO Regional Reference Laboratory (RRL), housed at 
the Medical Research Council Unit The Gambia at the London 
School of Hygiene and Tropical Medicine (MRCG), collabor-
ates with WHO to support hospital-based surveillance for inva-
sive bacterial vaccine-preventable disease (IB-VPD) across 10 
West and Central African countries, including Niger.
As part of the IB-VPD surveillance network, chil-
dren <5 years of age with suspected meningitis have cerebro-
spinal fluid (CSF) specimens collected for culture and latex 
agglutination at the sentinel-site hospital laboratory. CSF spe-
cimens are also sent to the WHO RRL for pathogen detection 
and serotyping/serogrouping using molecular techniques. The 
WHO RRL also performs antibiotic susceptibility testing and 
whole genome sequencing on S. pneumoniae isolates to provide 
insights on antibiotic resistance patterns and molecular epide-
miology of S.  pneumoniae, respectively. We analyzed the sur-
veillance data of IB-VPD from 2010 through 2016 to describe 
the distribution and the phenotypic and genotypic characteris-
tics of vaccine-preventable bacterial pathogens causing menin-
gitis and to monitor the impact of vaccination.
MATERIALS AND METHODS
Surveillance System and Patient Enrollment
The hospital-based surveillance was carried out at the Hopital 
National de Niamey, a large teaching hospital in Niamey, the 
capital city of Niger. Patients admitted to the reference hospital 
come from the 8 different regions in the country. Suspected 
meningitis cases were defined as sudden onset of fever (>38.5°C 
rectal or 38.0°C axillary) and combination of any or all of the 
following clinical symptoms; reduced level of consciousness, 
stiff neck, and bulging fontanelle if patient is <1  year old. 
Suspected meningitis cases admitted to the hospital underwent 
lumbar puncture to obtain CSF for diagnostic testing. Probable 
meningitis cases were suspected cases with at least 1 of the fol-
lowing CSF characteristics: turbid appearance, white blood cell 
count (WBC) of >100 cells/μL or WBC count of 10–100 cells/
μL and either an elevated protein (>100 mg/dL) or decreased 
glucose (<40 mg/dL). Confirmed meningitis cases were those 
who had a pathogen detected in the CSF collected.
Laboratory Methods
Based on macroscopic appearance, CSF specimens were 
classified as clear, turbid, xanthochromic, or blood stained. 
Microscopic analysis grouped WBC count into 3 groups: ≤10 
cells/μL, 10–100 cells/μL, and >100 cells/μL. Gram staining 
was performed on all CSF specimens collected for the pre-
sumptive identification of S.  pneumoniae, N.  meningitidis, 
and H.  influenzae. Latex agglutination was performed 
using a Pastorex meningitis kit (Bio-Rad) for detecting Hib, 
S.  pneumoniae, and N.  meningitidis groups A, B, C, Y, and 
W antigens, following the manufacturer’s instructions. The 
BINAX NOW kit (Alere), when available, was used for the 
detection of S.  pneumoniae antigen. Microbiological culture 
was done for the isolation of S. pneumoniae, N. meningitidis, 
and H. influenzae. CSF specimens were streaked on Columbia 
blood agar and chocolate agar plates for isolation of pure col-
onies. Antimicrobial susceptibility testing was performed by 
the disk diffusion method at the sentinel site laboratory, and 
Etest was done at the WHO RRL. Both methods were done ac-
cording to the 2017 Clinical and Laboratory Standards Institute 
guidelines [9].
At the WHO RRL, real-time polymerase chain reaction 
(qPCR) for autolysin gene (lytA), protein D encoding gene 
(hpd), and CU, Zn superoxide dismutase gene (sodC) was 
perfomed for the detection of S. pneumoniae, H. influenzae, and 
N. meningitidis, respectively. Neisseria meningitidis serogroups 
A, B, C, W, X, and Y were detected by targeting sacB, synD, 
synE, synG, xcbB, and synF genes, respectively. Haemophilus 
influenzae serotypes a, b, c, d, e, and f were detected by targeting 
acsB, bcsB, ccsD, dcsE, ecsH, and bexD, respectively. A total of 37 
different S. pneumoniae serotypes were targeted using a sequen-
tial multiplex qPCR assay [10]. Nontypeable S.  pneumoniae 
with cycle threshold values ≤32 by qPCR underwent serotyping 
by conventional multiplex PCR [11].
Whole Genome Sequencing Analysis of S. pneumoniae Isolates
DNA was extracted from S. pneumoniae isolates using a modi-
fied QIAGEN kit according to the manufacturer’s instructions. 
Whole genome sequencing was performed using Illumina 
Hiseq 2500.
Sequencing reads from each isolate were mapped onto the 
S.  pneumoniae ATCC 700669 serotype 23F reference genome 
using SMALT [12], and pseudo-genomes were placed in a mul-
tiple sequence alignment using custom scripts. Single-nucleotide 
polymorphisms (SNPs) were called from the pseudo-alignment 
using SNP sites. A maximum likelihood phylogeny was recon-
structed with a general time reversible model using randomized 
accelerated maximum likelihood (RAxML) [13] and visualized 
in iTOL [14]. Genotypic antimicrobial resistance prediction 
was also done for the S. pneumoniae isolates.
Statistical Analysis
Patient data were entered in an Epi Info database tool at the sen-
tinel site and sent to the WHO RRL where PCR data were en-
tered. Fisher exact test was done using Stata version 12 software 
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(StataCorp, College Station, Texas) to determine associations 
between CSF characteristics and PCR results. Percentages were 
calculated in Microsoft Excel software and presented on tables 
and as prose.
Ethical Considerations
Ethical approval was not a requirement in Niger for routine 
meningitis surveillance, including drug susceptibility testing of 
collected isolates, as this was approved within the routine diag-
nostic algorithm at the Ministry of Health. However, informed 
consent was sought from the parents or guardians of the sur-
veillance participants. Additionally, the surveillance received 
overarching ethical approval (SCC1188) by the joint Medical 
Research Council/The Gambia Government ethics board that 
allowed the analysis of collected West African isolates at MRCG.
RESULTS
A total of 2580 suspected meningitis cases among chil-
dren <5 years of age were reported during the 2010–2016 sur-
veillance period (Table 1). More than half of the cases were 
males and more than a third of children were in their first year 
of life. We screened 81% (2085/2580) of suspected cases for bac-
terial pathogens at the sentinel site and/or at the WHO RRL. Of 
this number, 13% (273/2085) were confirmed meningitis cases; 
48% (131/273) N. meningitidis, 45% (123/273) S. pneumoniae, 
and 7% (19/273) H.  influenzae. None of the infants that had 
confirmed S. pneumoniae had a record of PCV13 vaccination. 
However, it is important to note that the PCV13 vaccination 
record is unknown for 78.2% (2017/2580) of participants in the 
surveillance.
In total, 339 CSF samples were sent to the WHO RRL for sero-
typing/serogrouping during the surveillance period (Table 2). 
Prior to PCV13 introduction, the WHO RRL only received 
2% of CSF specimens from suspected cases, whereas after 
PCV13, 22% of CSF specimens were sent to WHO RRL for 
PCR. Streptococcus pneumoniae meningitis decreased from 
34 cases in 2014 to 16 cases in 2016. Overall, 88% (7/8) of all 
S.  pneumoniae meningitis cases prior to PCV13 (2010–2013) 
that were serotyped were caused by PCV13 serotypes. PCV13 
serotypes were only responsible for 20% (5/25) of S. pneumoniae 
serotyped cases post-PCV13 (2014–2016). Serogroup results 
for 17 N. meningitidis cases were obtained. NmC was respon-
sible for 59% (10/17) and N.  meningitidis serogroup W was 
responsible for 35% (6/17). The NmC cases were all detected 
in 2016. No NmA cases were reported throughout the surveil-
lance. Haemophilus influenzae meningitis was uncommon, with 
19 cases reported. Out of this number, 84% (16/19) were <1 year 
old. Of the 3 confirmed cases with serotype data, 2 were Hib.
Disaggregating the results by year, N.  meningitidis domin-
ated except in 2013 and 2014 when S. pneumoniae was the most 
common pathogen (Figure 1). When the data were segregated 
by month, the highest number of suspected meningitis cases 
was reported during March and April, with 26% (681/2580) 
of suspected cases occurring in these 2 months. Streptococcus 
pneumoniae was the deadliest pathogen, with a case fatality rate 
(CFR) of 23%. The CFRs of N. meningitidis and H. influenzae 
were 13% and 11%, respectively. The number of suspected men-
ingitis cases admitted and the total number of children who 
died fluctuated over the years of the surveillance (Figure 2). The 
CFR was highest in 2012 (16%).
Among confirmed meningitis cases with recorded data, 84% 
(126/150) had seizures, 65% (70/107) had reduced level of con-
sciousness, and 69% (77/111) had neck stiffness. Among con-
firmed cases, 33% (19/57) presented with bulging fontanel, and 
90.0% (17/19) of this number were <2 years old.
 The majority of patients (67% [1588/2372]) had a clear 
CSF and <1% (12/2372) had a xanthochromic CSF specimen. 
A  strong association between turbidity of CSF and a positive 
PCR result was noted (P < .001). For instance, a pathogen was 
detected in 71% (40/56) of the turbid CSF specimens tested. 
Likewise, patients with a WBC count of >100 cells/μL were 
more likely to be infected with a bacterial pathogen (P < .001) 
compared with patients with WBC count <100 cells/μL.
Phylogenetic analysis and antimicrobial susceptibility 
testing was performed for 25 S.  pneumoniae isolates (Figure 
3). Of the 25 S. pneumoniae isolates, 23 were collected in the 
pre-PCV13 era and 2 were collected in the post-PCV13 era. 
PCV13 S.  pneumoniae made up 84% (21/25) of all the iso-
lates collected. Serotype 1 was the most frequently detected 
S. pneumoniae serotype among the isolates (40% [10/25]). The 
data also show a close relationship among serotype 1 isolates, all 
of which belonged to clonal complex 217 (CC217). Resistance 
to trimethoprim-sulfamethoxazole (SXT) and tetracycline 
was widespread, with 72% (18/25) of S.  pneumoniae isolates 
Table 1. Characteristics of Children Aged <5 Years Admitted at Hopital 
National de Niamey With Suspected Meningitis (N = 2580)
Characteristic No. (%)
Age, mo   
 0–11 1106 (42.9)
 12–23 431 (16.7)
 24–59 1006 (39.0)
 Unknown 37 (1.4)
Sex   
 Male 1539 (59.7)
 Female 1017 (39.4)
 Unknown 24 (0.9)
Antibiotic before admission   
 Yes 127 (4.9)
 No 375 (14.5)
 Unknown 2078 (80.5)
Final outcome   
 Discharged alive 1349 (52.3)
 Died 263 (10.2)
 Unknown 968 (37.5)
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expressing resistance to SXT and 76% (19/25) expressing re-
sistance to tetracycline. Resistance to tetracycline was common 
among serotype 1 isolates, with 80% (8/10) expressing resist-
ance. We found that 16% (4/25) of S. pneumoniae isolates were 
resistant to penicillin. In total, there were 6 resistance genotypes 
that were detected by genotypic resistance prediction and not 
expressed in their corresponding phenotypic resistance profiles. 
The folA/P gene (mutations within the gene confers resistance 
against SXT) was the gene detected for 4 such cases.
DISCUSSION
Neisseria meningitidis was the predominant etiologic agent 
among confirmed meningitis cases, although there were some 
years that S.  pneumoniae meningitis exceeded the number of 
N.  meningitidis meningitis. Streptococcus pneumoniae was the 
deadliest pathogen with CFR of 23%. We found some resistance 
to penicillin, and high resistance to SXT was observed among 
S. pneumoniae isolates.
We have reported data from hospital-based surveillance 
describing the magnitude and etiology of suspected menin-
gitis among children <5 years old admitted to a large tertiary 
care hospital in Niger from 2010 to 2016. Surveillance data 
are helpful to inform and evaluate immunization policies by 
describing the epidemiology of the disease in the country and 
monitor impact.
Real-time PCR is more sensitive than culture-based methods 
and was thus used at the WHO RRL for confirming cases as 
well as providing serotyping data [15]. Comprehensive sero-
typing data are crucial for evaluating the impact of the vaccines 
targeting bacterial meningitis pathogens. The overall detection 
of the 3 pathogens appears to have decreased following mass 
vaccinations with MenAfriVac and introduction of Hib and 
Figure 1. Bar graph showing yearly distribution of Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. The line graph on the secondary axis 
shows the case fatality rate of the 3 pathogens.
Table 2. Cerebrospinal Fluid Specimens Received and Tested at the World Health Organization Regional Reference Laboratory
Year
Total WHO RRL 
Cases, No.
CSF Samples Received/
Tested at WHO RRL, No.
No. of Confirmed 
Cases, No.
Haemophilus 
influenzae, No. (%)
Streptococcus 
pneumoniae, No. (%)
Neisseria 
meningitidis, 
No. (%)
2010 459 6 1 0 (0) 1 (100) 0 (0)
2011 210 6 5  1 (20) 4 (80) 0 (0)
2012 214 4 3  1 (33) 2 (67) 0 (0)
2013 223 1 0 0 (0) 0 (0) 0 (0)
2014 488 124 30 0 (0) 24 (80) 6 (20)
2015 584 97 6  1 (17) 3 (50) 2 (33)
2016 402 101 20 0 (0) 9 (45) 11 (55)
Total 2580 339 65 3 (5) 43 (66) 19 (29)
Abbreviations: CSF, cerebrospinal fluid; RRL, Regional Reference Laboratory; WHO, World Health Organization.
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PCV13 in the infant immunization program in Niger. A 2002–
2008 surveillance carried out by Maïnassara and colleagues 
found S. pneumoniae, N. meningitidis, and H. influenzae detec-
tion rate of 40.81% (5229/12811) [6], whereas we present a de-
tection rate of 13.1% (273/2085).
Before the mass immunization campaign against NmA, 
N. meningitidis was by far the most common cause of menin-
gitis in Niger [16, 17]. However, our data show the increasing 
importance of S.  pneumoniae as a causative agent of menin-
gitis in Niger. It was almost as prevalent as N.  meningitidis. 
Furthermore, in 2013 and 2014, there were more S. pneumoniae 
meningitis than N.  meningitidis cases. The decrease in 
N. meningitidis meningitis can be attributed to the effectiveness 
of the MenAfriVac vaccine. However, the serogroup A  speci-
ficity of MenAfriVac has raised concerns that other serogroups 
may arise as an important cause of N. meningitidis meningitis 
in the African meningitis belt regions. Based on our analysis, 
NmC now represents >50% of N. meningitidis identified. This 
is a concern given that NmC has the potential to cause large 
outbreaks as demonstrated in Nigeria with the emergence of a 
previously unknown hypervirulent NmC strain [18]. The same 
strain was the etiologic agent of the meningitis outbreak in 
Niger in 2015. A monovalent conjugate vaccine against NmC 
is currently licensed for use. Vaccination is the most effective 
strategy for reducing incidence of NmC meningitis as demon-
strated in countries with routine use of monovalent C conju-
gate vaccine [19]. However, due to cost consideration in African 
countries, the NmC vaccine is only rolled out during outbreaks, 
targeting the most affected age groups and districts. At the mo-
ment, the best approach to control outbreaks caused by this 
strain in Niger is to strengthen surveillance and put response 
systems in place. This would ensure timely diagnosis and man-
agement of case contacts to minimize the risk of transmission.
Our data also show the decline in H. influenzae meningitis 
when compared to the pre-Hib vaccine era [20]. However, 19 
cases were still detected in the surveillance and the most vulner-
able population was children <1 year old. Attempts to further 
improve vaccine coverage to further reduce this number should 
be a priority. Countries such as Senegal and The Gambia have 
reported a near elimination of Hib meningitis [21, 22].
We have shown that the number of confirmed S. pneumoniae 
meningitis cases decreased after 2014. However, due to the small 
number of S. pneumoniae meningitis cases with serotype infor-
mation available pre-PCV13, we were unable to compare sero-
type distribution pre- and post-PCV13. More data are needed 
to show changes in serotype distribution. The high CFR of 
S. pneumoniae meningitis is in accordance with studies done in 
the country prior to PCV13 introduction [17]. Although cases 
of S. pneumoniae meningitis decreased after 2014, this was not 
followed by a concurrent decrease in the CFR of S. pneumoniae. 
The CFR remained fairly stable throughout the surveillance pe-
riod. Sequence type 217 clonal complex, common in Africa [23, 
24], was the most dominant S. pneumoniae lineage in our sur-
veillance. The lineage was the etiologic agent of the 2005 men-
ingitis outbreak in the Kassena-Nankana district within Ghana 
[25].
Infections caused by S.  pneumoniae resistant to penicillin 
have increased at an alarming rate over the years [26–28]; this 
trend was also noticed in our surveillance, as we detected 4 iso-
lates that were resistant to oxacillin (a penicillin-class antibiotic). 
Penicillin resistance of carriage S. pneumoniae isolates was also 
observed among children <2 years old in Niger [29]. We found 
Figure 2. Outcome of meningitis cases by year.
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high resistance of S. pneumoniae isolates to SXT, which could be 
explained by their indiscriminate and widespread use in Africa. 
A study conducted in Finland has shown that the development 
of S. pneumoniae resistance to SXT is affected by the consump-
tion rate of the antibiotic [30]. SXT is not used to treat menin-
gitis in Niger. However, the Joint United Nations Programme on 
HIV/AIDS and the World Health Organization recommended 
the antibiotic to be used for prophylaxis in both children and 
adult living with human immunodeficiency virus (HIV)/AIDS 
in Africa to prevent severe bacterial infections, opportunistic 
infections, and malaria [31]. Strategies such as sensitization 
programs should be prioritized to reduce the indiscriminate 
consumption of SXT among persons living without HIV or 
those without severe or advanced HIV clinical disease.
A major limitation of this analysis is the low number of CSF 
specimens sent to the WHO RRL for analysis prior to PCV13 in-
troduction. This limited our ability to evaluate changes in sero-
typing distribution post-PCV13. In addition, the surveillance 
is hospital-based and our observations cannot be generalized 
to the rest of the country. Last, vaccination history was not re-
corded for the majority of cases.
CONCLUSIONS
We have shown a reduction in S. pneumoniae meningitis fol-
lowing PCV13 introduction. However, we were unable to prop-
erly evaluate changes in serotype distribution of S. pneumoniae 
meningitis because not all cases of S.  pneumoniae meningitis 
were serotyped. We have also shown the emergence of NmC as 
an important cause of meningitis. The findings of this analysis 
support the need to improve and continue surveillance of men-
ingitis and characterization of bacterial pathogens to provide 
additional data for further analysis to better understand the ep-
idemiology of meningitis in Niger.
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